NASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Price, News & Analysis $2.95 +0.05 (+1.72%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.86▼$3.0050-Day Range$2.14▼$5.2852-Week Range$1.87▼$38.20Volume587,641 shsAverage Volume993,722 shsMarket Capitalization$207.98 millionP/E RatioN/ADividend YieldN/APrice Target$15.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Ventyx Biosciences alerts: Email Address Ventyx Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside433.9% Upside$15.75 Price TargetShort InterestBearish15.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.31) to ($2.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector705th out of 936 stocksPharmaceutical Preparations Industry329th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingVentyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageVentyx Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Ventyx Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.87% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Ventyx Biosciences has recently increased by 5.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTYX. Previous Next 2.6 News and Social Media Coverage News SentimentVentyx Biosciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ventyx Biosciences this week, compared to 4 articles on an average week.MarketBeat Follows2 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders18.18% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ventyx Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.31) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ventyx Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Ventyx Biosciences Stock (NASDAQ:VTYX)Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.Read More VTYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTYX Stock News HeadlinesJuly 20, 2024 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 19, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (9EP.F)July 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 25, 2024 | globenewswire.comVENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for DetailsJune 22, 2024 | globenewswire.comVENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for DetailsJune 20, 2024 | globenewswire.comVENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading SchemeJune 18, 2024 | globenewswire.comVENTYX INSIDER TRADING ALERT: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding LossesJune 13, 2024 | globenewswire.comVENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the FirmJuly 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 11, 2024 | globenewswire.comVENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's BoardJune 8, 2024 | globenewswire.comVENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of DirectorsJune 6, 2024 | globenewswire.comBREAKING VENTYX ALERT: Ventyx (Nasdaq: VTYX) Stock Declines 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of DirectorsJune 5, 2024 | globenewswire.comVentyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory MarkersJune 3, 2024 | globenewswire.comVENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 16, 2024 | globenewswire.comVentyx Biosciences to Participate in Three Upcoming Investor ConferencesMay 16, 2024 | msn.comVentyx Biosciences gets new operations chiefMay 16, 2024 | markets.businessinsider.comVentyx Biosciences Appoints Moore As COOMay 16, 2024 | globenewswire.comVentyx Biosciences Announces Appointment of Matthew Moore as Chief Operating OfficerSee More Headlines Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VTYX CUSIPN/A CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.75 High Stock Price Target$62.00 Low Stock Price Target$5.00 Potential Upside/Downside+433.9%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.94% Return on Assets-59.87% Debt Debt-to-Equity RatioN/A Current Ratio22.00 Quick Ratio22.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.71Miscellaneous Outstanding Shares70,500,000Free Float57,682,000Market Cap$207.98 million OptionableOptionable Beta0.39 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Sheila K. Gujrathi M.D. (Age 54)Executive Chairperson Comp: $125kDr. Raju S. Mohan Ph.D. (Age 66)Founder, CEO, President & Director Comp: $905.29kDr. John M. Nuss Ph.D. (Age 65)Chief Scientific Officer Comp: $630.63kDr. Martin Douglas Auster M.D. (Age 49)Chief Financial Officer Key CompetitorsNuvation BioNYSE:NUVBEvolusNASDAQ:EOLSWave Life SciencesNASDAQ:WVEPhibro Animal HealthNASDAQ:PAHCStoke TherapeuticsNASDAQ:STOKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 84,984 shares on 7/26/2024Ownership: 0.327%SG Americas Securities LLCBought 13,878 shares on 7/12/2024Ownership: 0.020%Simplicity Wealth LLCSold 7,044 shares on 7/10/2024Ownership: 0.032%Opaleye Management Inc.Bought 145,000 shares on 5/29/2024Ownership: 1.823%Farallon Capital Management LLCBought 3,170,000 shares on 5/24/2024Ownership: 4.496%View All Insider TransactionsView All Institutional Transactions VTYX Stock Analysis - Frequently Asked Questions How have VTYX shares performed this year? Ventyx Biosciences' stock was trading at $2.47 at the start of the year. Since then, VTYX stock has increased by 19.4% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.05. When did Ventyx Biosciences IPO? Ventyx Biosciences (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share. Who are Ventyx Biosciences' major shareholders? Ventyx Biosciences' top institutional investors include Bank of New York Mellon Corp (0.33%), Simplicity Wealth LLC (0.03%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Somu Subramaniam, Nsv Partners Iii Lp, Raju Mohan, Christopher W Krueger, John Nuss, William J Sandborn, Martin Auster, Global Strategic Fund I Venbio and Sheila Gujrathi. View institutional ownership trends. How do I buy shares of Ventyx Biosciences? Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VTYX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
